FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations By Ogkologos - August 29, 2025 610 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR ¿Las píldoras anticonceptivas afectan mi riesgo de cáncer? April 18, 2023 New on NCI’s Websites for October 2019 October 3, 2019 Mathew Knowles, Father Of Beyoncé, Fought And Beat Breast Cancer November 5, 2019 El cáncer en mi comunidad: Cómo superar las desigualdades en la... January 3, 2023 Load more HOT NEWS 38% of Recurrent Breast Cancers Have a Different HER2 Status than... A coming together of minds for early detection Low Risk of Cardiotoxicity with Immune Checkpoint Inhibitor Monotherapy or Combination... FDA Approves Engineered Cell Therapy for Advanced Synovial Sarcoma
